DOCSLIB.ORG

Estonian Statistics on Medicines 2017 1/42

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Estonian Statistics on Medicines 2017 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 169,5987 A01 STOMATOLOGICAL PREPARATIONS 0,0723 A01A STOMATOLOGICAL PREPARATIONS 0,0723 A01AA Caries prophylactic agents A01AA01 Sodium fluoride (dental) 51 g A01AB Antiinfectives and antiseptics for local oral treatment 0,0723 A01AB09 Miconazole (O) 6958,4 g 0,2 g 0,0723 A01AB12 Hexetidine (O) 1802400 ml A01AB81 Neomycin+ Benzocaine (dental) 30900 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 460 g A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 210860 g A01AD81 Lidocaine+ Cetrimide (O) 34685 g A01AD82 Choline salicylate (O) 780560 pieces A01AD83 Lidocaine+ Chamomille extract (O) 371950 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 528 g A02 DRUGS FOR ACID RELATED DISORDERS 48,6099 A02A ANTACIDS 1,0401 Combinations and complexes of aluminium, calcium and A02AD 1,0401 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 768200 pieces 10 pieces 0,1597 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3461134 ml 50 ml 0,1439 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3543408 pieces 10 pieces 0,7366 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 47,5697 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,1028 A02BA02 Ranitidine (O) 300308,25 g 0,3 g 2,0808 A02BA02 Ranitidine (P) 3175,75 g 0,3 g 0,022 A02BC Proton pump inhibitors 45,4595 A02BC01 Omeprazole (O) 257962,34 g 0,02 g 26,8113 A02BC02 Pantoprazole (O) 196205,1 g 0,04 g 10,1963 A02BC02 Pantoprazole (P) 461,2 g 0,04 g 0,024 A02BC03 Lansoprazole (O) 10,5 g 0,03 g 0,0007 A02BC05 Esomeprazole (O) 118787,76 g 0,03 g 8,2308 A02BC05 Esomeprazole (P) 2834,8 g 0,03 g 0,1964 A02BD Combinations for eradication of Helicobacter pylori <0,0001 A02BD08 Bismuth subcitrate+ Tetracycline+ Metronidazole (O) 120 pieces 12 pieces <0,0001 Other drugs for peptic ulcer and gastro-oesophageal reflux A02BX 0,0073 disease (GORD) A02BX02 Sucralfate (O) 13850 g 4 g 0,0072 A02BX05 Bismuth subcitrate (O) 33,6 g 0,48 g 0,0001 A02BX80 Vonoprazan (O) 3 g DRUGS FOR FUNCTIONAL GASTROINTESTINAL A03 7,9427 DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL A03A 7,0126 DISORDERS A03AA Synthetic anticholinergics, esters with tertiary amino group 0,9891 A03AA04 Mebeverine (O) 142746 g 0,3 g 0,9891 A03AB Synthetic anticholinergics, quaternary ammonium compounds <0,0001 A03AB02 Glycopyrronium (P) 0,006 g 3 mg <0,0001 A03AD Papaverine and derivatives 4,4561 A03AD01 Papaverine hydrochloride (P) 66,2 g 0,1 g 0,0014 A03AD02 Drotaverine (O) 210001,28 g 0,1 g 4,3653 A03AD02 Drotaverine (P) 4303 g 0,1 g 0,0894 A03AX Other drugs for functional gastrointestinal disorders 1,5674 A03AX13 Simeticone (O) 377005,5437 g 0,5 g 1,5674 A03B BELLADONNA AND DERIVATIVES, PLAIN 0,0905 1/42 Estonian Statistics on Medicines 2017 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A03BA Belladonna alkaloids, tertiary amines 0,0782 A03BA01 Atropine (O, P) 17,34 g 0,0015 g 0,024 A03BA01 Atropine (P) 39,08 g 0,0015 g 0,0542 Belladonna alkaloids, semisynthetic, quaternary ammonium A03BB 0,0123 compounds A03BB01 Hyoscine butylbromide (O) 51,8 g 0,06 g 0,0018 A03BB01 Hyoscine butylbromide (P) 297,9 g 0,06 g 0,0103 A03BB01 Hyoscine butylbromide (R) 6,24 g 0,06 g 0,0002 A03F PROPULSIVES 0,8396 A03FA Propulsives 0,8396 A03FA01 Metoclopramide (O) 9698 g 0,03 g 0,672 A03FA01 Metoclopramide (P) 1874,9 g 0,03 g 0,1299 A03FA03 Domperidone (O) 544,14 g 0,03 g 0,0377 A04 ANTIEMETICS AND ANTINAUSEANTS 0,1243 A04A ANTIEMETICS AND ANTINAUSEANTS 0,1243 A04AA Serotonin (5-HT3) antagonists 0,1107 A04AA01 Ondansetron (P) 34,76 g 0,016 g 0,0045 A04AA02 Granisetron (O) 59,76 g 0,002 g 0,0621 A04AA02 Granisetron (P) 63,61 g 0,003 g 0,0441 A04AD Other antiemetics 0,0136 A04AD01 Scopolamine (TD) 10 pieces 1 pieces <0,0001 A04AD12 Aprepitant (O) 332,025 g 0,095 g 0,0073 A04AD81 Fosaprepitant (P) 288,45 g 0,095 g 0,0063 A05 BILE AND LIVER THERAPY 2,2636 A05A BILE THERAPY 0,4938 A05AA Bile acid preparations 0,4938 A05AA02 Ursodeoxycholic acid (O) 178150 g 0,75 g 0,4938 A05B LIVER THERAPY, LIPOTROPICS 1,7698 A05BA Liver therapy 1,7698 A05BA03 Silymarin (O) 2644490 pieces A05BA80 Essential phospholipids (O) 2554230 pieces 3 pieces 1,7698 A05BA80 Essential phospholipids (P) 1945 pieces A06 DRUGS FOR CONSTIPATION 15,5975 A06A DRUGS FOR CONSTIPATION 15,5975 A06AB Contact laxatives 7,4335 A06AB02 Bisacodyl (O) 14969,2 g 0,01 g 3,1116 A06AB02 Bisacodyl (R) 999 g 0,01 g 0,2077 A06AB06 Senna glycosides (O) 8440 pieces 1 pieces 0,0175 A06AB08 Sodium picosulfate (O) 9852,8073 g 0,005 g 4,0962 A06AB80 Sodium picosulfate+ Magnesium oxide+ Citric acid (O) 460 pieces 2 pieces 0,0005 A06AC Bulk-forming laxatives <0,0001 A06AC01 Hemicellulose of Ispaghula (O) 0,585 g 7 g <0,0001 A06AD Osmotically acting laxatives 7,3069 A06AD11 Lactulose (O) 22314644,9 g 6,7 g 6,9232 A06AD15 Macrogol (O) 1846000 g 10 g 0,3837 Macrogol+ Sodium citrate+ Citric acid+ Sodium chloride+ A06AD80 14400 ml Potassium chloride (O) Sodium sulphate, anhydrous+ Potassium chloride+ Sodium A06AD81 58596 pieces chloride+ Macrogol+ Sodium hydrogen carbonate (O) Macrogol+ Sodium sulphate, anhydrous+ Sodium chloride+ A06AD83 280 pieces Potassium chloride+ Ascorbic acid+ Sodium ascorbate (O) Sodium sulphate, anhydrous+ magnesium sulfate A06AD85 796224 ml heptahydrate+ Potassium sulphate (O) A06AG Enemas 0,8499 A06AG11 Laurilsulfate, incl. combinations+ Sorbitol+ Sodium citrate (R) 408872 pieces 1 pieces 0,8499 A06AH Peripheral opioid receptor antagonists 0,0071 2/42 Estonian Statistics on Medicines 2017 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A06AH03 Naloxegol (O) 85,5 g 25 mg 0,0071 ANTIDIARRHEALS, INTESTINAL A07 4,0713 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07A INTESTINAL ANTIINFECTIVES 0,0003 A07AA Antibiotics 0,0003 A07AA02 Nystatin (O) 20000000 U 1500000 U <0,0001 A07AA06 Paromomycin (O) 42 g A07AA11 Rifaximin (O) 55,2 g 0,6 g 0,0002 A07AA12 Fidaxomicin (O) 8 g 0,4 g <0,0001 A07B INTESTINAL ADSORBENTS 0,4412 A07BC Other intestinal adsorbents 0,4412 A07BC05 Diosmectidum (O) 1910070 g 9 g 0,4412 A07C ELECTROLYTES WITH CARBOHYDRATES A07CA Oral rehydration salt formulations Sodium chloride+ Potassium chloride+ Sodium citrate+ A07CA80 68200 pieces Glucose (O) A07D ANTIPROPULSIVES 0,9968 A07DA Antipropulsives 0,9968 A07DA03 Loperamide (O) 4795,472 g 0,01 g 0,9968 A07DA06 Eluxadoline (O) 16,8 g A07E INTESTINAL ANTIINFLAMMATORY AGENTS 2,0161 A07EA Corticosteroids acting locally 0,0023 A07EA06 Budesonide (O) 9,99 g 0,009 g 0,0023 A07EA06 Budesonide (R) 0,9352 g A07EC Aminosalicylic acid and similar agents 2,0137 A07EC01 Sulfasalazine (O) 796650 g 2 g 0,828 A07EC02 Mesalazine (O) 788185 g 1,5 g 1,0923 A07EC02 Mesalazine (R) 67458 g 1,5 g 0,0935 A07F ANTIDIARRHEAL MICROORGANISMS 0,617 A07FA Antidiarrheal microorganisms 0,617 A07FA02 Saccharomyces boulardii (O) 296797,5 g 1 g 0,617 A07X OTHER ANTIDIARRHEALS A07XA Other antidiarrheals A07XA04 Racecadotril (O) 3311 g A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 0,0522 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 0,0522 A08AA Centrally acting antiobesity products 0,0363 A08AA62 Bupropione+ Naltrexone (O) 69776 pieces 4 pieces 0,0363 A08AB Peripherally acting antiobesity products 0,016 A08AB01 Orlistat (O) 2766,96 g 0,36 g 0,016 A09 DIGESTIVES, INCL. ENZYMES 1,4828 A09A DIGESTIVES, INCL. ENZYMES 1,4828 A09AA Enzyme preparations 1,4827 A09AA02 Lipase+ Amylase+ Protease (O) 2853211 pieces 4 pieces 1,4827 A09AC Enzyme and acid preparations, combinations 0,0001 A09AC80 Pepsin+ Betaine (O) 150 pieces 3 pieces 0,0001 A10 DRUGS USED IN DIABETES 62,3756 A10A INSULINS AND ANALOGUES 16,3017 A10AB Insulins and analogues for injection, fast-acting 6,1563 A10AB01 Insulin (human) (P) 874500 U 40 U 0,0454 A10AB04 Insulin lispro (P) 25911000 U 40 U 1,3465 A10AB05 Insulin aspart (P) 77940000 U 40 U 4,0503 A10AB06 Insulin glulisine (P) 13738500 U 40 U 0,714 A10AC Insulins and analogues for injection, intermediate-acting 0,1188 A10AC01 Insulin (human) (P) 2286000 U 40 U 0,1188 Insulins and analogues for injection, intermediate- or long- A10AD 1,2917 acting combined with fast-acting 3/42 Estonian Statistics on Medicines 2017 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A10AD04 Insulin lispro (P) 8655000 U 40 U 0,4498 A10AD05 Insulin aspart (P) 16201500 U 40 U 0,842 A10AE Insulins and analogues for injection, long-acting 8,7349 A10AE04 Insulin glargine (P) 102192750 U 40 U 5,3107 A10AE05 Insulin detemir (P) 65892000 U 40 U 3,4242 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 46,0739 A10BA Biguanides 20,0821 A10BA02 Metformin (O) 19321782 g 2 g 20,0821 A10BB Sulfonylureas 14,4784 A10BB07 Glipizide (O) 1154,55 g 0,01 g 0,24 A10BB09 Gliclazide (O) 232998,6 g 0,06 g 8,0722 A10BB12 Glimepiride (O) 5932,68 g 0,002 g 6,1661 A10BD Combinations of oral blood glucose lowering drugs 5,0782 A10BD07 Metformin+ Sitagliptin (O) 2025856 pieces 2 pieces 2,1056 A10BD08 Metformin+ Vildagliptin (O) 949140 pieces 2 pieces 0,9865 A10BD10 Metformin+ Saxagliptin (O) 321240 pieces 2 pieces 0,3339 A10BD11 Metformin+ Linagliptin (O) 769740 pieces 2 pieces 0,8 A10BD15 Metformin+ Dapagliflozin (O) 255024 pieces 2 pieces 0,2651 A10BD19 Linagliptin+ Empagliflozin (O) 17910 pieces 1 pieces 0,0372 A10BD20 Metformin+ Empagliflozin (O) 495780 pieces 2 pieces 0,5153 A10BD21 Saxagliptin+ Dapagliflozin (O)
Recommended publications
  • Successful Treatment of Rifampicin Resistant Case of Leprosy by WHO Recommended Ofloxacin and Minocycline Regimen

    Successful Treatment of Rifampicin Resistant Case of Leprosy by WHO Recommended Ofloxacin and Minocycline Regimen

    Lepr Rev (2019) 90, 456–459 CASE REPORT Successful treatment of rifampicin resistant case of leprosy by WHO recommended ofloxacin and minocycline regimen MALLIKA LAVANIAa, JOYDEEPA DARLONGb, ABHISHEK REDDYb, MADHVI AHUJAa, ITU SINGHa, R.P. TURANKARa & U. SENGUPTAa aStanley Browne Laboratory, The Leprosy Mission Community Hospital, Nand Nagri, New Delhi 110093, India bThe Leprosy Mission Hospital, Purulia, West Bengal 723101, India Accepted for publication 15 July 2019 Summary A 25-year-old male treated for leprosy at the age of 15, with MDT, visited TLM Purulia Hospital in July 2017. He was provisionally diagnosed as a lepromatous relapse with ENL reaction. A biopsy was done to test for drug resistance. Drug resistance testing showed resistance to rifampicin. Second line drug regimen recommended by WHO for rifampicin-resistance was started. Within 6 months of taking medication the clinical signs and symptoms improved rapidly and the BI dropped by 1·66 log within 6 months. This case highlights the need for investigations in cases of relapse and the efficacy of WHO recommended second line drug regimen treatment in rifampicin-resistant leprosy cases. Keywords: leprosy, rifampicin-resistance, second-line treatment Introduction Leprosy, also known as Hansen’s disease (HD), is a chronic infectious disease caused by the bacterium Mycobacterium leprae or Mycobacterium lepromatosis.1,2 Leprosy is curable with administration of a rifampicin, clofazimine and dapsone known as multidrug therapy (MDT). Since the introduction of MDT in 1983 the prevalence
  • WO 2017/048702 Al

    WO 2017/048702 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
  • Sofosbuvir/Ledipasvir for HIV •

    Sofosbuvir/Ledipasvir for HIV •

    Hepatitis C: Drugs and Combinations Melissa Osborn MD Associate Professor MetroHealth Medical Center Case Western Reserve University Cleveland, OH Faculty and Planning Committee Disclosures Please consult your program book. Off-Label Disclosure The following off-label/investigational uses will be discussed in this presentation: • Sofosbuvir/ledipasvir for HIV •. Investigational agents for hepatitis C will be mentioned – Asunaprevir – Daclatasvir – Beclabuvir – Grazoprevir – Elbasvir – GS-5816 Learning Objectives Upon completion of this presentation, learners should be better able to: • apply clinical trial data on new hepatitis C therapies to their patient population. • select which new hepatitis C therapies are appropriate to use with common antiretrovirals. Evolution of interferon-based therapy in HCV-monoinfected genotype 1 patients Sustained Virologic Response 100% 90% 80% 80% 75% 67% 60% 42% 46% 40% 28% 20% 7% 0% Std interferon-alfa IFN + RBV Peg-alfa-2b+RBV Peg-alfa-2a +RBV P/R/Telaprevir P/R/Boceprevir P/R/Simeprevir P/R/Sofosbuvir McHutchison, NEJM 1998; 339: 1485-92 Jacobson, NEJM 2011; 364:2405-16 Fried, NEJM 2002; 347: 975-82 Poordad, NEJM 2011; 364: 1195-206 Manns, Lancet 2001; 358:958-65 Jacobson, AASLD 2013 #1122 Lawitz, NEJM 2013 Evolution of HCV Therapy: Genotype 1 Patients Naïve to Therapy: HIV-HCV coinfection Sustained Virologic Response 80% 75% 74% 67% 61% 60% 46% 42% 40% 28% 29% 20% 17% 7% 7% 0% Std interferon-alfa IFN + RBV Peg-alfa-2b+RBV Peg-alfa-2a +RBV P/R/Telaprevir P/R/Boceprevir Torriani, NEJM, 2004 351:438-50
  • Hepatitis C Agents Therapeutic Class Review

    Hepatitis C Agents Therapeutic Class Review

    Hepatitis C Agents Therapeutic Class Review (TCR) November 2, 2018 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004–2018 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Mfr FDA-Approved Indications Interferons peginterferon alfa-2a Genentech Chronic hepatitis C (CHC) 1 (Pegasys®) .
  • Clofazimine As a Treatment for Multidrug-Resistant Tuberculosis: a Review

    Clofazimine As a Treatment for Multidrug-Resistant Tuberculosis: a Review

    Scientia Pharmaceutica Review Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review Rhea Veda Nugraha 1 , Vycke Yunivita 2 , Prayudi Santoso 3, Rob E. Aarnoutse 4 and Rovina Ruslami 2,* 1 Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia; [email protected] 2 Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia; [email protected] 3 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran—Hasan Sadikin Hospital, Bandung 40161, Indonesia; [email protected] 4 Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, 6255HB Nijmegen, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by Mycobac- terium tuberculosis which is resistant to at least isoniazid and rifampicin. This disease is a worldwide threat and complicates the control of tuberculosis (TB). Long treatment duration, a combination of several drugs, and the adverse effects of these drugs are the factors that play a role in the poor outcomes of MDR-TB patients. There have been many studies with repurposed drugs to improve MDR-TB outcomes, including clofazimine. Clofazimine recently moved from group 5 to group B of drugs that are used to treat MDR-TB. This drug belongs to the riminophenazine class, which has lipophilic characteristics and was previously discovered to treat TB and approved for leprosy. This review discusses the role of clofazimine as a treatment component in patients with MDR-TB, and Citation: Nugraha, R.V.; Yunivita, V.; the drug’s properties.
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • Where Do Novel Drugs of 2016 Fit In?

    Where Do Novel Drugs of 2016 Fit In?

    FORMULARY JEOPARDY: WHERE DO NOVEL DRUGS OF 2016 FIT IN? Maabo Kludze, PharmD, MBA, CDE, BCPS, Associate Director Elizabeth A. Shlom, PharmD, BCPS, SVP & Director Clinical Pharmacy Program Acurity, Inc. Privileged and Confidential August 15, 2017 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ◆ Identify orphan drugs and first-in-class medications approved by the FDA in 2016. ◆ Describe the role of new agents approved for use in oncology patients. ◆ Identify and discuss the role of novel monoclonal antibodies. ◆ Discuss at least two new medications that address public health concerns. Neither Dr. Kludze nor Dr. Shlom have any conflicts of interest in regards to this presentation. Privileged and Confidential 2016 NDA Approvals (NMEs/BLAs) ◆ Nuplazid (primavanserin) P ◆ Adlyxin (lixisenatide) ◆ Ocaliva (obeticholic acid) P, O ◆ Anthim (obitoxaximab) O ◆ Rubraca (rucaparib camsylate) P, O ◆ Axumin (fluciclovive F18) P ◆ Spinraza (nusinersen sodium) P, O ◆ Briviact (brivaracetam) ◆ Taltz (ixekizumab) ◆ Cinqair (reslizumab) ◆ Tecentriq (atezolizumab) P ◆ Defitelio (defibrotide sodium) P, O ◆ Venclexta (venetoclax) P, O ◆ Epclusa (sofosburvir and velpatasvir) P ◆ Xiidra (lifitigrast) P ◆ Eucrisa (crisaborole) ◆ Zepatier (elbasvir and grazoprevir) P ◆ Exondys 51 (eteplirsen) P, O ◆ Zinbyrta (daclizumab) ◆ Lartruvo (olaratumab) P, O ◆ Zinplava (bezlotoxumab) P ◆ NETSTPOT (gallium Ga 68 dotatate) P, O O = Orphan; P = Priority Review; Red = BLA Privileged and Confidential History of FDA Approvals Privileged and Confidential Orphan Drugs ◆FDA Office of Orphan Products Development • Orphan Drug Act (1983) – drugs and biologics . “intended for safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S.
  • WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T

    WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 9/26 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US20 17/024981 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 30 March 2017 (30.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/3 15,400 30 March 2016 (30.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/457,584 10 February 2017 (10.02.2017) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 15/473,994 30 March 2017 (30.03.2017) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: AMICUS THERAPEUTICS, INC.
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment

    Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment

    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
  • Combination Therapy for Peptic Ulcer Treatment

    Combination Therapy for Peptic Ulcer Treatment

    Office europeen des brevets © Publication number: 0 480 691 A2 © EUROPEAN PATENT APPLICATION © Application number : 91309249.0 © int. ci.5: A61K 33/24, A61K 31/60, A61K 31/44, A61K 31/425, © Date of filing : 09.10.91 //(A61K33/24, 31:44, 31:425), (A61K31/60, 31:44, 31:425), (A61K31/44, 31:195), (A61K31/425, 31:195) © Priority: 11.10.90 US 595908 © Inventor: Berlin, Roger G. 519 Mulberry Lane Haverford, PA 19041 (US) (43) Date of publication of application : 15.04.92 Bulletin 92/16 @ Representative : Thompson, John Dr. et al Merck & Co., Inc. European Patent @) Designated Contracting States : Department Terlings Park Eastwick Road CH DE FR GB IT LI NL Harlow, Essex CM20 2QR (GB) © Applicant : MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 Rahway New Jersey 07065-0900 (US) © Combination therapy for peptic ulcer treatment. © Peptic ulcer disease is treated with a combination therapy of famotidine or omeprazole plus a bismuth salt. CM < CO o 00 LU Jouve, 18, rue Saint-Denis, 75001 PARIS EP 0 480 691 A2 BACKGROUND OF THE INVENTION In the past, treatment of peptic ulcer disease was based on either neutralization of intragastric acidity with antacids or the inhibition of production of acid secretion by H2-receptor antagonists or by proton pump inhibition 5 among others. Using bismuth salts alone to heal ulcers has been shown to be effective presumably because of its effect on Helicobacter pylori. Relapse of Helicobacter positivity, however, has been a problem as has relapse of ulcer disease in patients treated with antisecretory therapy.
  • Annex I Summary of Product Characteristics

    Annex I Summary of Product Characteristics

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT NutropinAq 10 mg/2 ml (30 IU) solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One cartridge contains 10 mg (30 IU) of somatropin* * human growth hormone produced in Escherichia coli cells by recombinant DNA technology. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. NutropinAq is a solution for subcutaneous use. The clear, colourless, sterile solution for multidose use is contained in a glass cartridge, closed with a rubber stopper and a rubber seal. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications - Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. - Long-term treatment of growth failure associated with Turner syndrome. - Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. - Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment (see section 4.4). 4.2 Posology and method of administration Diagnosis and therapy with somatropin should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of patients with the therapeutic indication of use. The NutropinAq dosage and administration schedule should be individualised for each patient. Dosage Growth failure in children due to inadequate growth hormone secretion: 0.025 - 0.035 mg/kg bodyweight given as a daily subcutaneous injection. Somatropin therapy should be continued in children and adolescents until their epiphysis are closed.
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center

    Penile Injection Therapy | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.